The global DNases, ligases, and RNA polymerases market size was valued at USD 611.97 million in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 8.58% from 2022 to 2030. The market is witnessing growth due to the factors such as the increasing demand for gene therapy and cancer immunotherapy and the growing demand for mRNA-based vaccines. Moreover, DNases are critical for inexpensive and sustainable production of novel biocatalysts, leveraged bioprocesses, and cost-efficient product recovery processes. A significant rise in the adoption of ligases for recombinant DNA experiments is also projected to accelerate the growth of the market over the forecast period. Extensive focus on innovation using mRNA and its leveraged production is driving the market along with the demand for mRNA-based vaccine production for COVID-19.
Wide applications of DNase in biological activities are expected to drive the market for DNase. DNase is used for the inexpensive and sustainable production of novel biocatalysts, leveraged bioprocesses, and cost-efficient product recovery processes. DNase has beneficial effects on inflammatory diseases. For instance, Recombinant human DNase lowers the viscosity of in lungs and is a helpful therapeutic step in the treatment of cystic fibrosis. The rise in consistent research efforts in life sciences and the rise in the demand for gene therapy across the globe are anticipated to be strong drivers for the market.
Ligase is an enzyme that uses adenosine triphosphate to develop bonds, and it is appropriately used in DNA recombinant cloning techniques so as to attach restriction endonuclease fragments. T4 DNA ligase (isolated from E. coli) is the ligase that is usually used in molecular biology applications such as next-generation sequencing and cloning. An increase in research funding to develop ligases to be used as a target for therapeutic applications in cancer is estimated to drive the segment in the forecast period.
Ribonucleic acid polymerase (RNA polymerase) inhibitors work to block the enzyme RNA polymerase in a cell. The blocking of RNA polymerase helps to fix the mutated DNA part of cancerous cells and is hence an appealing target for drug development due to its functional utility. Prokaryotes have one multi-subunit RNA polymerase whereas eukaryotes have multiple RNA polymerases that are specialized for the synthesis of different types of RNAs. For instance, RNA polymerase I produce rRNA, RNA polymerase II produces mRNAs and miRNAs, and RNA polymerase III produces tRNAs and rRNAs.
Moreover, the COVID-19 pandemic situation has offered lucrative opportunities for RNA polymerase applications. Currently, there are over 150 vaccines and therapeutics that either use mRNA in their production processes or are based on mRNA molecules, which are being assessed for the treatment of a wide range of indications. Many mRNA vaccines are approved for emergency use in many countries across the globe. For instance, in March 2022, Moderna’s mRNA-1273 received FDA approval for EUA of the second booster dose of its COVID-19 vaccine.
Research becomes an integral and continuous process in the evolution of technologies. Research institutes play a primary role in the initiation of research activities, with a deeper understanding of the features of the human genome. Moreover, research leads to customization of research utilities and DNases, ligases, and RNA polymerases for subjective utility in research activities such as gene cloning, gene silencing, and genetic engineering. For instance, in November 2021, BOC RNA, a pharmaceutical raw material supplier company, based in New York, expanded its oligo synthesis services to meet the needs of customers in the biomedical business.
The other applications segment dominated the market with a revenue share of over 65.0% in 2021. Other applications comprise possible treatment of cystic fibrosis, COPD, and asthma; prediction of common diseases; and forensic applications. Recombinant human DNase1 is a widely used mucolytic agent in individuals with cystic fibrosis. By cleaving DNA, DNase1 reduces the abnormal thickness of cystic fibrosis mucus in vitro and enhances lung function and airway clearance in cystic fibrosis patients. Moreover, enzyme DNases are used in forensic applications, and the most widely utilized is HaeIII for forensic DNA analysis, which cuts DNA at the sequence 5'-GGCC-3'.
The biopharmaceutical processing segment is expected to expand at a CAGR of 8.3% over the forecast period. This is attributed to the factors such as an increase in the adoption of DNA enzymes related to pharmaceuticals, which are essential for the treatment of various chronic diseases and digestive disorders. In addition, developments in the biotechnology and pharmaceutical fields, such as the introduction of genetic and protein engineering, have helped in expanding applications of enzymes, which is expected to offer lucrative growth opportunities in the forecast period.
The other applications segment held the largest share of over 55.0% in 2021. Other applications include in vitro gene manipulation, analysis of protein-protein interactions and DNA sequencing, and catalyzing the formation of phosphodiester bonds in DNA & RNA molecules. The DNA ligase from T4 bacteriophage is one of the widely used enzymes in molecular biology. DNA ligases are used for various applications in biotechnology and molecular biology. Many times, they have been used in the detection of mutation using ligation chain reaction and construction of recombinant DNA molecules.
The oligonucleotide segment is expected to witness significant growth in the coming years. Oligonucleotide synthesis, the biochemical synthesis of nucleic acids, has emerged as an essential tool in the area of molecular biology. Synthetic oligonucleotides have been used in several applications such as diagnosis of infectious and genetic diseases, disease treatment, and new drug discovery. With 12 oligonucleotide drugs moving to the ligases market in 2021 and more than hundreds in preclinical development and clinical trials, the most recent stage in the development of a product in oligonucleotide manufacturing poses a cost liability to manufacturers.
The mRNA production segment dominated the RNA polymerase market with a revenue share of over 75.0% in 2021. The year 2020 was a breakout year for mRNA technology platforms, with the unveiling and extensive usage of mRNA vaccines for coronavirus. The applications of RNA, both in clinical R&D and basic research, have expanded after developments in the field of molecular biology have considerably improved the in vitro reliability of such molecules. At present, there are over 150 vaccines and therapeutics that either use mRNA in their production processes or are based on mRNA molecules, which are being assessed for the treatment of a wide range of indications.
Many mRNA vaccines for COVID-19 are approved for emergency use in many countries across the globe and there are increasing capital investments for the development of mRNA vaccines. For instance, in June 2021, Sanofi declares an investment of around USD 452.12 annually for its mRNA vaccines development center.
The other applications segment is expected to register a CAGR of 8.5% in the forecast period. RNA polymerase plays a key role in transcription, cDNA synthesis, and synthesis of antisense RNA and dsRNA. RNA polymerase is the key transcription enzyme, and transcription begins when RNA polymerase binds to a supporter sequence near the beginning of a gene.
North America led the market with a share of over 35.0% in 2021 and is anticipated to grow lucratively over the forecast period. The factors such as the increase in the adoption of DNA enzymes that can be used for drug development and are essential for different therapeutic regimes to treat chronic disorders and digestive diseases. Furthermore, RNA polymerases are in high demand after the COVID-19 pandemic in the U.S. due to the demand for mRNA vaccines. RNA polymerases are also regularly used in drug development processes for the treatment of infections caused by tuberculosis and leprosy. Moreover, many novel mRNA-based vaccines are in various stages of development for a wide variety of cancers. Increasing cases of infectious diseases will boost market growth in the forecast period.
Asia Pacific is expected to expand at the fastest CAGR of 9.33% during the forecast period. Significant developments in Japan and China for technological integration and rapid healthcare development, clinical development frameworks, and growing R&D in emerging economies such as Australia and India have created significant opportunities in the Asia Pacific, which is anticipated to boost the market growth in the region during the forecast period.
Key companies operating in the market are focusing on strategic collaborations, partnerships, and regional expansion. For instance, in September 2021, SpeeDx Pty, Ltd. invested in SynGenis Pty Ltd., an oligonucleotide manufacturer in Australia. The partnership will strengthen the capacity of SpeeDx to sustain a large-scale increase in manufacturing. Moreover, the firms are working on expansion strategies for deeper penetration of the market space and to maintain an efficient supply chain.
Some prominent players in the global DNases market include:
Merck KGaA/ Sigma Aldrich
Thermo Fisher Scientific
New England Biolabs
Some prominent players in the global ligases market include:
Thermo Fisher Scientific
New England Biolabs
Some prominent players in the global RNA polymerases market include:
Merck BPS Bioscience, Inc.
Sino Biological, Inc.
New England Biolabs
Thermo Fisher Scientific
Market size value in 2022
USD 661.79 million
Revenue forecast in 2030
USD 1.28 billion
CAGR of 8.58% from 2022 to 2030
Base year for estimation
2018 - 2020
2022 - 2030
Revenue in USD million and CAGR from 2022 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; U.K.; Germany; Spain; Italy; France; Japan; China; India; Singapore; Australia; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE
Key companies profiled
Key players in DNases market are Merck KGaA/ Sigma Aldrich; Takara Bio; Calzyme; Thermo Fisher Scientific; Promega Corporation; QIAGEN; Agilent Technologies; RayBiotech; New England Biolabs; and Abnova Corporation.
Key players in ligases market are Thermo Fisher Scientific; New England Biolabs; RayBiotech; Agilent Technologies; ABclonal Technology; BioVision; Promega Corporation; MBL International; Blirt; and MyBioSource.
Key players in RNA polymerases market are Merck BPS Bioscience, Inc.; Novus Biologicals; Sino Biological, Inc.; MyBioSource; RayBiotech; New England Biolabs; Thermo Fisher Scientific; Biorbyt; Agilent Technologies; and Promega Corporation.
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the applications of DNases, ligases, and RNA polymerases from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the global DNases, ligases, and RNA polymerases market report on the basis of application and region:
DNases Application Outlook (Revenue, USD Million, 2018 - 2030)
Ligases Application Outlook (Revenue, USD Million, 2018 - 2030)
RNA Polymerase Application Outlook (Revenue, USD Million, 2018 - 2030)
Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East & Africa
b. The global DNases, ligases, RNA polymerases market size was estimated at USD 611.97 million in 2021 and is expected to reach USD 661.79 million in 2022.
b. The global DNases, ligases, RNA polymerases market is expected to grow at a compound annual growth rate of 8.58% from 2022 to 2030 to reach USD 1.28 billion by 2030.
b. North America dominated the DNases, ligases, RNA polymerases market with a share of 39.16% in 2021. This is attributable to increase in adoption of DNA enzymes that can be used for drug development, which are essential for different therapeutic regimes to treat chronic disorders and digestive diseases. Moreover, many novel mRNA based vaccines are under various stages of development for a wide variety of cancers.
b. Some key players operating in the DNases, ligases, RNA polymerases market include Merck KGaA/ Sigma Aldrich, Takara Bio, Calzyme, Thermo Fisher Scientific, New England Biolabs, RayBiotech, Agilent Technologies, BPS Bioscience Inc., Novus Biologicals, Sino Biological, Inc., MyBioSource and Abnova Corporation.
b. Key factors that are driving the market growth include increasing demand for gene therapy & cancer immunotherapy and growing demand for mRNA-based vaccines. Furtheremore, significant rise in adoption of ligases for recombinant DNA experiments is also projected to accelerate the growth of Dnases, ligases, RNA polymerases market over the forecast period.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."